Baricitinib plus Remdesivir may shorten COVID-19 recovery ti
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Eli Lilly’s arthritis drug Baricitinib, when combined with remdesivir, reduced recovery time for COVID-19 patients by about a day compared to patients receiving remdesivir alone, the company announced.

Baricitinib is marketed as Olumiant and is indicated to treat moderate to severe rheumatoid arthritis patients who did not have adequate results with a TNF inhibitor. It has been the subject of several COVID-19 clinical trials.

Key findings:

• Phase 3 COVID-19 Treatment Trial (ACTT-2) started on May 8 and enrolled more than 1,000 hospitalized COVID-19 patients, who randomly received either a 4-mg dose of baricitinib plus remdesivir or remdesivir alone.

• Primary outcome was the reduction in time to recovery. In the study, “recovery” was defined as being well enough to leave the hospital and no longer need supplemental oxygen or ongoing inpatient medical care, or was no longer in the hospital by day 29.

• Baricitinib plus remdesivir group exhibited an estimated one-day reduction median recovery time compared to the remdesivir alone group, which the investigators said was a “statistically significant” finding.

• Analyses of the study data are still ongoing, with NIAID expected to eventually publish the results in a peer-reviewed journal.

Source: https://investor.lilly.com/news-releases/news-release-details/baricitinib-combination-remdesivir-reduces-time-recovery
Dr. T●●●●z H●●●●●●i and 6 others like this2 shares
Like
Comment
Share